2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Pregnant, Young Adult
PAPER

2691 Less is enough: A physiology-based approach to intravenous iron dosing in pregnancy reduces iron administration without compromising maternal hemoglobin response

Mark Chaitowitz, MD, Josette Kamel, MD2
1 Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States
2 Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States

Background

The role of intravenous iron in the treatment of iron deficiency in pregnant women is firmly established. However, scant attention has been paid to iron dosing, and a “one-size-fits-all” approach of administration of a standard 1g has been commonly adopted. We previously developed a pregnancy-specific modified Ganzoni formula that estimates iron requirements using maternal weight, hemoglobin, and gestational age. Similar to the traditional Ganzoni formula, our calculator originally incorporated a fixed 500 mg component intended to replenish iron stores. Because this additional iron is not required for maternal erythropoiesis and may theoretically increase maternal hepcidin, potentially limiting placental iron transfer, we hypothesized that omission of this component would substantially reduce administered iron without compromising correction of maternal anemia.

Methods

The analyzed cohort consisted of patients referred between November 2025 and June 2026 to e-Iron, which is an EMR-based telemedicine platform for the triage and expedited management of iron deficiency patients. Doses were calculated using the pregnancy-specific modified Ganzoni formula calculator, rounded to the nearest 100 mg. Out of a theoretical concern that the additional iron load might paradoxically inhibit iron transfer across the placenta, from April 2026 a modified formula was used, wherein the fixed 500 mg component (“standard dosing” [StdD]), was changed to 50 mg (“modified dosing” [ModD]).  The primary endpoints were Hb at delivery and change in Hb from referral to delivery.

Results

A total of 122 women were included, of which 76 received StdD, and 46 received ModD. The mean Hb at time of referral was 9.27 g/dL.

Patients received either ferric carboxymaltose (47/122) or iron dextran (75/122). All patients in the ModD group were able to complete their treatment with a single infusion. In the StdD group, the calculated dose exceeded 1 g in 7 patients, necessitating 2 infusions.  

Mean administered iron dose was 1,020 ± 233 mg (range, 750–1,800 mg) in the StdD group, versus  565 ± 173 mg (range, 300–950 mg) in the ModD group (p<0.001).

Mean Hb improvement from referral to delivery was 1.73 ± 1.17 g/dL in the StdD group compared with 1.43 ± 1.19 g/dL in the ModD group (p = 0.155). Hb >11 g/dL at delivery was achieved in 34/76 (44.7%) StdD patients compared with 15/46 (32.6%) ModD patients (p = 0.257).

Because the ModD dosing protocol was introduced later in the study period, many patients had not yet delivered by the analytic cutoff and were thus unavailable for outcome analysis. Consequently, patients included in the ModD cohort had a significantly shorter interval from infusion to delivery (44.0 ± 32.6 days vs 26.2 ± 17.3 days; p<0.001), a strong predictor of Hb response.

Multivariable linear regression adjusting for baseline hemoglobin and the interval from infusion to delivery demonstrated that dosing strategy was not independently associated with Hb improvement (β = −0.15 g/dL; 95% CI −0.51 to 0.21; p = 0.402). Independent predictors of greater Hb improvement were lower baseline hemoglobin (β = −0.72 g/dL per 1 g/dL higher baseline Hb; 95% CI −0.93 to −0.51; p < 0.001) and longer time from infusion to delivery (β = +0.0088 g/dL/day; 95% CI 0.003–0.015; p = 0.006).

Conclusions

Use of a physiology-based approach to calculate iron dosing in iron deficient pregnant women addresses the needs of a sizeable proportion of this population, whose iron requirement either significantly exceeds the standard 1g, or, whose iron requirement is substantially less. Our analysis further suggests that within the framework of personalized calculated dosing, omission of the empiric 500 mg iron stores component decreased administered iron by approximately 45%, without compromising correction of maternal anemia, an important predictor of maternal and fetal morbidity and mortality.  

While the impetus for reducing IV iron dose is a theoretical concern that delivery of an IV iron dose in excess of that required for maternal erythropoiesis might result in prolonged maternal hepcidin elevation and thus inhibit transfer of iron to the fetus, we note that this hypothesis is speculative. Much work remains to better elucidate the complex relation between maternal iron status, maternal IV iron dosing, and long term offspring outcomes. Growing evidence that adequate fetal iron availability is critical for normal neurodevelopment underscores the importance of such studies.

Mark Chaitowitz, MD: No relevant conflicts of interest to declare.